Research communication triclosan inhibit the growth of the late liver-stage of plasmodium

IUBMB Life

Volumn 61, Issue 9, 2009, Pages 923-928

  Singh, Agam Prasad ^a,b   Surolia, Namita ^c   Surolia, Avadhesha ^a,c  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH   (India)

Author keywords

Liver stage parasites; Malaria; Novel antimalarial; Prophylactic drug

Indexed keywords

TRICLOSAN;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIVER CELL; NONHUMAN; PLASMODIUM BERGHEI; ANIMAL; CELL LINE; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; LIVER; PARASITOLOGY; PLASMODIUM FALCIPARUM;

PLASMODIUM FALCIPARUM;

ANIMALS; CELL LINE; HUMANS; LIVER; PLASMODIUM FALCIPARUM; TRICLOSAN;

EID: 70350752494     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.237     Document Type: Article

References (37)

1. Guinovart, C., Navia, M. M., Tanner, M., and Alonso, P. L. (2006) Malaria: burden of disease. Curr. Mol. Med. 6, 137-140.
2. Amino, R., Thiberge, S., Martin, B., Celli, S., Shorte, S., Frischknecht, F., and Menard, R. (2006) Quantitative imaging of Plasmodium transmission from mosquito to mammal. Nat. Med. 12, 220-224.
3. Prudencio, M., Rodriguez, A., and Mota, M. M. (2006) The silent path to thousands of merozoites: the Plasmodium liver stage. Nat. Rev. Microbiol. 4, 849-856.
4. World Health Organization (2005). WHO World Malaria Report. World Health Organization: Geneva, Switzerland. Available at: http://rbm.who.int/wmr2005.
5. Mutabingwa, T. K., Anthony, D., Heller, A., Hallett, R., Ahmed, J., Drakeley, C., Greenwood, B. M., and Whitty, C. J. (2005) Amodiaquine alone, amodiaquine1sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 365, 1474-1480.
6. Surolia, N., and Surolia, A. (2001) Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nat. Med. 7, 167-173.
7. Rock, C. O., and Cronan, J. E. (1996) Escherichia coli as a model for the regulation of dissociable (Type II) fatty acid biosynthesis. Biochim. Biophys. Acta. 1302, 1-16.
8. Smith, S., Witkowski, A., and Joshi, A. K. (2003) Structural and functional organization of the animal fatty acid synthase. Prog. Lipid Res. 42, 289-317.
9. Ralph, S. A., van Dooren, G. G., Waller, R. F., Crawford, M. J., Fraunholz, M. J., Foth, B. J., Tonkin, C. J., Roos, D. S., and McFadden, G. I. (2004) Tropical infectious diseases: metabolic maps and functions of the Plasmodium falciparum apicoplast. Nat. Rev. Microbiol. 2, 203-216.
10. Heath, R. J., and Rock, C. O. (1995) Enoyl-acyl carrier protein reductase (fabI) plays a determinant role in completing cycles of fatty acid elongation in Escherichia coli. J. Biol. Chem. 270, 26538-26542.
11. Wiesner, J., and Seeber, F. (2005) The plastid-derived organelle of protozoan human parasites as a target of established and emerging drugs. Expert Opin. Ther. Targets 9, 23-44.
12. Perozzo, R., Kuo, M., Sidhu, A. S., Valiyaveettil, J. T., Bittman, R., Jacobs, W. R. Jr., Fidock, D. A., and Sacchettini, J. C. (2002) Structural elucidation of the specificity of the antibacterial agent triclosan for malarial enoyl acyl carrier protein reductase. J. Biol. Chem. 277, 13106-13114.
13. Zhang, Y. M., Lu, Y. J., and Rock, C. O. (2004) The reductase steps of the Type II fatty acid synthase as antimicrobial targets. Lipids 39, 1055-1060.
14. Kapoor, M., Dar, M. J., Surolia, A., and Surolia, N. (2001) Kinetic determinants of the interaction of enoyl-ACP reductase from Plasmodium falciparum with its substrates and inhibitors. Biochem. Biophys. Res. Commun. 289, 832-837.
15. Kapoor, M., Reddy, C. C., Krishnasastry, M. V., Surolia, N., and Surolia, A. (2004) Slow-tight-binding inhibition of enoyl-acyl carrier protein reductase from Plasmodium falciparum by triclosan. Biochem. J. 381, 719-724.
16. Kapoor, M., Mukhi, P. L., Surolia, N., Suguna, K., and Surolia, A. (2004) Kinetic and structural analysis of the increased affinity of enoyl-ACP (acyl-carrier protein) reductase for triclosan in the presence of NAD+. Biochem. J. 381, 725-733.
17. Kapoor, M., Gopalakrishnapai, J., Surolia, N., and Surolia, A. (2004) Mutational analysis of the triclosan-binding region of enoyl-ACP (acyl-carrier protein) reductase from Plasmodium falciparum. Biochem. J. 381, 735-741.
18. Suguna, K., Surolia, A., and Surolia, N. (2001) Structural basis for triclosan and NAD binding to enoyl-ACP reductase of Plasmodium falciparum. Biochem. Biophys. Res. Commun. 283, 224-228.
19. Pidugu, L. S., Kapoor, M., Surolia, N., Surolia, A., and Suguna, K. (2004) Structural basis for the variation in triclosan affinity to enoyl reductases. J. Mol. Biol. 343, 147-155.
20. Sharma, S., Ramya, T. N., Surolia, A., and Surolia, N. (2003) Triclosan as a systemic antibacterial agent in a mouse model of acute bacterial challenge. Antimicrob. Agents Chemother. 47, 3859-3866.
21. Zhou, Y., Ramachandran, V., Kumar, K. A., Westenberger, S., Refour, P., Zhou, B., Li, F., Young, J. A., Chen, K., Plouffe, D., Henson, K., Nussenzweig, V., Carlton, J., Vinetz, J. M., Duraisingh, M. T., and Winzeler, E. A. (2008) Evidence-based annotation of the malaria parasite's genome using comparative expression profiling. PLoS ONE 3, e1570.
22. Vaughan, A. M., O'Neill, M. T., Tarun, A. S., Camargo, N., Phuong, T. M., Aly, A. S., Cowman, A. F., and Kappe, S. H. (2008) Type II fatty acid synthesis is essential only for malaria parasite late liver stage development. Cell. Microbiol. 11, 506-520.
23. Yu, M., Kumar, T. R., Nkrumah, L. J., Coppi, A., Retzlaff, S., Li, C. D., Kelly, B. J., Moura, P. A., Lakshmanan, V., Freundlich, J. S., Valderramos, J. C., Vilcheze, C., Siedner, M., Tsai, J. H., Falkard, B., Sidhu, A. B., Purcell, L. A., Gratraud, P., Kremer, L., Waters, A. P., Schiehser, G., Jacobus, D. P., Janse, C. J., Ager, A., Jacobs, W.R. Jr., Sacchettini, J. C., Heussler, V., Sinnis, P., Fidock, D. A. (2008) The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites. Cell Host Microbe 4, 567-578.
24. Valecha, N., Adak, T., Bagga, A. K., Asthana, O. P., Srivastava, J. S., Joshi, H., and Sharma, V. P. (2001) Comparative antirelapse efficacy of CDRI compound 80/53 (Bulaquine) vs primaquine in double blind clinical trial. Curr. Sci. 80, 561-563.
25. Walsh, D. S., Wilairatana, P., Tang, D. B., Heppner, D. G. Jr., Brewer, T. G., Krudsood, S., Silachamroon, U., Phumratanaprapin, W., and Siriyanonda, D. (2004). Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clin. Infect. Dis. 39, 1095-1103.
26. Neerja, J., and Puri, S. K. (2004) Plasmodium yoelii: activity of azithromycin in combination with pyrimethamine or sulfadoxine against blood and sporozoite induced infections in Swiss mice. Exp. Parasitol. 107, 120-124.
27. Singh, N., and Puri, S. K. (1998) Causal prophylactic activity of antihistaminic agents against Plasmodium yoelii nigeriensis infection in Swiss mice. Acta Trop. 69, 255-260. (Pubitemid 28243247)
28. Lindenthal, C., Weich, N., Chia, Y. S., Heussler, V., and Klinkert, M. Q. (2005) The proteasome inhibitor MLN-273 blocks exoerythrocytic and erythrocytic development of Plasmodium parasites. Parasitology 131, 37-44. (Pubitemid 41008807)
29. Singh, A. P., Buscaglia, C. A., Wang, Q., Levay, A., Nussenzweig, D. R., Walker, J. R., Winzeler, E. A., Fujii, H., Fontoura, B. M. A., and Nussenzweig, V. (2007) Plasmodium circumsporozoite protein promotes the development of the liver stages of the parasite. Cell 131, 492-504.
30. McConkey, G. A., Rogers, M. J., and McCutchan, T. F. (1997) Inhibition of Plasmodium falciparum protein synthesis. Targeting the plastid-like organelle with thiostrepton. J. Biol. Chem. 272, 2046-2049.
31. Waller, R. F., Keeling, P. J., Donald, R. G., Striepen, B., Handman, E., Lang-Unnasch, N., Cowman, A. F., Besra, G. S., Roos, D. S., and McFadden, G. I. (1998) Nuclear-encoded proteins target to the plastid in Toxoplasma gondii and Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 95, 12352-12357.
32. McMurray, L. M., Oethinger, M., and Levy, S. B. (1998) Triclosan targets lipid synthesis. Nature 394, 531-532.
33. Heath, R. J., Yu, Y. T., Shapiro, M. A., Olson, E., and Rock, C. O. (1998) Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis. J. Biol. Chem. 273, 30316-30320.
34. Tarun, A. S., Peng, X., Dumpit, R. F., Ogata, Y., Silva-Rivera, H., Camargo, N., Daly, T. M., Bergman, L. W., and Kappe, S. H. (2008) A combined transcriptome and proteome survey of malaria parasite liver stages. Proc. Natl. Acad. Sci. USA 105, 305-310.
35. Sharma, S., Sharma, S. K., Modak, R., Karmodiya, K., Surolia, N., and Surolia, A. (2007) Mass spectrometry-based systems approach for identification of inhibitors of Plasmodium falciparum fatty acid synthase. Antimicrob. Agents Chemother. 51, 2552-2558.
36. Kumar, G., Parasuraman, P., Sharma, S. K., Banerjee, T., Karmodiya, K., Surolia, N., and Surolia, A. (2007) Discovery of a rhodanine class of compounds as inhibitors of Plasmodium falciparum enoyl-acyl carrier protein reductase. J. Med. Chem. 50, 2665-2675.
37. Tasdemir, D., Lack, G., Brun, R., Ruedi, P., Scapozza, L., and Perozzo, R. (2006) Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J. Med. Chem. 49, 3345-3353.